Eris Lifesciences Limited has reported strong financial performance for the quarter and year ended March 31, 2026. The company announced a consolidated net profit of ₹647.51 crore for the full financial year. Alongside these results, the Board of Directors declared an interim dividend of ₹7.21 per share for the 2026-2027 financial year, payable to eligible shareholders on or before June 19, 2026.
Consolidated Financial Performance
For the fiscal year ended March 31, 2026, Eris Lifesciences achieved a total revenue from operations of ₹3,129.42 crore, compared to ₹2,893.64 crore in the previous year. The company’s consolidated net profit stood at ₹647.51 crore, marking a significant increase from ₹374.67 crore reported in the prior fiscal year. The quarter ending March 31, 2026, saw a profit of ₹279.10 crore, driven by strong operational execution.
Strategic Acquisitions and Developments
The company continues to expand its footprint through strategic acquisitions. During FY 2026, Eris completed the acquisition of the remaining minority stake in Swiss Parenteral Limited and finalized the purchase of a Branded Probiotics Business from Velbiom Probiotics Private Limited for ₹50 crore. These moves align with the company’s commitment to growth and market consolidation within the pharmaceutical sector.
Interim Dividend Details
Reflecting its commitment to shareholder value, the Board has declared an interim dividend of ₹7.21 per share, representing a 721% payout on the face value of Re. 1 per share for the 2026-2027 financial year. Investors should note that Friday, May 29, 2026, has been fixed as the record date for determining eligibility for this dividend payment.
Tax Regime Transition
A notable highlight for the year was the company’s decision to opt for the concessional tax regime. This transition, effective for FY 2026-27, led to a re-measurement of deferred tax assets and liabilities, resulting in a deferred tax credit of ₹150 crore recognized in the statement of profit and loss.
Source: BSE
